InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

Current share price for ATX : $0.120 0.01 (7.69%)+

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$62 Half Yearly Report and Accounts 27 Nov 2025 4:44PM $0.140 $0.120 fallen by 14.29%
$62 Positive Response from US FDA to Amplia's Type D Meeting 20 Nov 2025 9:59AM $0.115 $0.120 risen by 4.35%
$62 Notification regarding unquoted securities - ATX 10 Nov 2025 4:42PM $0.130 $0.120 fallen by 7.69%
$62 Amplia Commences Trading on U.S. OTCQB Venture Market 31 Oct 2025 8:19AM $0.135 $0.120 fallen by 11.11%
$62 Quarterly Activities/Appendix 4C Cash Flow Report 29 Oct 2025 9:03AM $0.125 $0.120 fallen by 4%
$62 Amplia Receives R&D Tax Rebate Totalling $3.77 Million 28 Oct 2025 9:13AM $0.130 $0.120 fallen by 7.69%
$62 Amplia Therapeutics to Significantly Expand U.S. Presence 17 Oct 2025 10:33AM $0.145 $0.120 fallen by 17.24%
$62 ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL 9 Oct 2025 8:24AM $0.175 $0.120 fallen by 31.43%
$62 Notification of cessation of securities - ATX 8 Oct 2025 9:48AM $0.165 $0.120 fallen by 27.27%
$62 Patent Allowance for Key Narmafotinib Patent in US 30 Sep 2025 8:36AM $0.155 $0.120 fallen by 22.58%
$62 Change of Director's Interest Notice - Warwick Tong 8 Sep 2025 12:22PM $0.160 $0.120 fallen by 25%
$62 Change of Director's Interest Notice - Chris Burns 8 Sep 2025 12:21PM $0.160 $0.120 fallen by 25%
$62 Change of Director's Interest Notice - Robert Peach 8 Sep 2025 12:20PM $0.160 $0.120 fallen by 25%
$62 Change of Director's Interest Notice - Jane Bell 8 Sep 2025 12:19PM $0.160 $0.120 fallen by 25%
$62 Notification of cessation of securities - ATX 8 Sep 2025 12:17PM $0.160 $0.120 fallen by 25%
$62 FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL 4 Sep 2025 8:18AM $0.160 $0.120 fallen by 25%
$62 FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL 4 Sep 2025 8:18AM $0.160 $0.120 fallen by 25%
$62 Notification of cessation of securities - ATX 2 Sep 2025 5:48PM $0.170 $0.120 fallen by 29.41%
$62 NARMAFOTINIB ADOPTED AS NONPROPRIETARY DRUG NAME IN USA 2 Sep 2025 8:21AM $0.165 $0.120 fallen by 27.27%
$62 Notification regarding unquoted securities - ATX 1 Sep 2025 5:15PM $0.165 $0.120 fallen by 27.27%
$62 Notification regarding unquoted securities - ATX 1 Sep 2025 5:06PM $0.165 $0.120 fallen by 27.27%
$62 Notice under Section 708A(5)(e) of the Corporations Act 1 Sep 2025 9:49AM $0.165 $0.120 fallen by 27.27%
$62 Application for quotation of securities - ATX 1 Sep 2025 9:39AM $0.165 $0.120 fallen by 27.27%
$62 Application for quotation of securities - ATX 1 Sep 2025 9:35AM $0.165 $0.120 fallen by 27.27%
$62 AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL 29 Aug 2025 8:24AM $0.170 $0.120 fallen by 29.41%

26 - 50 of 524 results

Page 2 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.